MT
Minh T. Truong
Highly rated in
21
conditions

Dr. Minh T. Truong

Boston Medical Center
Boston, MA
Highly rated in
21
conditions
Specialties:Radiation Oncology
Experience:26 Years
Clinical Trials:Currently Recruiting for 4 Trials
Accepts:New PatientsMedicare
Highly rated in
21
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Minh T. Truong's experience treating your condition:
About Dr. Minh T. Truong

Minh Truong is a Radiation Oncologist in Boston, Massachusetts. Truong has been practicing medicine for over 26 years and is highly rated in 21 conditions, according to our data. Her top areas of expertise are Tongue Cancer, Laryngeal Cancer, Oral Squamous Cell Carcinoma, Throat Cancer, and Gamma Knife Radiosurgery. She is licensed to treat patients in Massachusetts. Truong is currently accepting new patients.

Her clinical research consists of co-authoring 77 peer reviewed articles and participating in 10 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Minh T. Truong it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Minh T. Truong accepts the following insurance:

  •  Ambetter
Call to see if your plan is accepted.
Locations
830 Harrison Ave, Boston, MA 02118
Background & Education
Graduate Institution
Other, 1997
Specialties
Radiation Oncology
Licenses
Radiology in MA
Hospital Affiliations
Boston Medical Center
Languages Spoken
English
Vietnamese
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: December 14, 2022
Intervention Type: Other, Drug, Radiation, Biological
Study Drugs: AtezolizumabCetuximabCisplatinDocetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Recruiting
Publish Date: October 27, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: CisplatinFluorouracilGemcitabine HydrochloridePaclitaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Recruiting
Publish Date: December 08, 2022
Intervention Type: Other, Drug, Biological, Radiation
Study Drugs: CisplatinNivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Enrollment Status: Recruiting
Publish Date: November 25, 2022
Intervention Type: Procedure, Drug
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Active, not recruiting
Publish Date: September 21, 2022
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active, not recruiting
Publish Date: October 27, 2022
Intervention Type: Radiation, Biological
Study Drug: Cetuximab
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Active, not recruiting
Publish Date: November 17, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: CapecitabineChemotherapyErlotinib hydrochlorideFluorouracilGemcitabine hydrochloride
Study Phase: Phase 3
The Feasibility and Outcome of Cyberknife® Stereotactic Radiosurgical Boost and Salvage Therapy for Head and Neck Cancer
Enrollment Status: Completed
Publish Date: January 17, 2018
Intervention Type: Radiation
Study Phase: Not Applicable
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active, not recruiting
Publish Date: April 08, 2022
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Active, not recruiting
Publish Date: September 07, 2022
Intervention Type: Other, Biological, Radiation
Study Drugs: CetuximabDurvalumab
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials -
77 Total Publications
18F FDG PET/CT Prediction of Treatment Outcomes in HPV-positive, Locally Advanced Oropharyngeal Cancer Receiving De-intensified Therapy: Results from NRG-HN002.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: May 25, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
TD
Dr. Thomas F. Delaney
Radiation Oncology | Radiology
Highly rated in
26
conditions
Radiation Oncology
Radiology

Mass General Brigham

Francis H. Burr Proton Therapy Center

55 Fruit St, 
Boston, MA 
 1.9 mi

Thomas Delaney is a Radiation Oncologist and a Radiologist in Boston, Massachusetts. Delaney has been practicing medicine for over 41 years and is highly rated in 26 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Chordoma, Bone Tumor, and Gamma Knife Radiosurgery. He is licensed to treat patients in Massachusetts, Vermont, and New Hampshire. Delaney is currently accepting new patients.

BA
Dr. Brian M. Alexander
Radiation Oncology
Highly rated in
23
conditions
Radiation Oncology

Brigham Health

Brigham And Womens Hospital

75 Francis St, 
Boston, MA 
 1.7 mi

Brian Alexander is a Radiation Oncologist in Boston, Massachusetts. Alexander has been practicing medicine for over 19 years and is highly rated in 23 conditions, according to our data. His top areas of expertise are Brain Tumor, Glioblastoma, Astrocytoma, Gamma Knife Radiosurgery, and Tissue Biopsy. He is licensed to treat patients in Massachusetts. Alexander is currently accepting new patients.

HS
Dr. Helen A. Shih
Radiation Oncology
Highly rated in
23
conditions
Radiation Oncology

Mass General Brigham

Francis H. Burr Proton Therapy Center

30 Fruit St, 
Boston, MA 
 1.9 mi

Helen Shih is a Radiation Oncologist in Boston, Massachusetts. Shih has been practicing medicine for over 23 years and is highly rated in 23 conditions, according to our data. Her top areas of expertise are Brain Tumor, Metastatic Brain Tumor, Meningioma, Gamma Knife Radiosurgery, and Tissue Biopsy. She is licensed to treat patients in Massachusetts. Shih is currently accepting new patients.